ASCO GU Conference Coverage
(CNN) Feb 16, 2019 - The way doctors typically approach kidney cancer treatment could be evolving.
Two separate studies published Saturday in the New England Journal of Medicine showed that renal cell cancer patients had significantly better outcomes when their treatment combined the targeted therapy drug axitinib, or Inlyta, with an...
(Reuters) Feb 16, 2019 - A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday.
Nearly 90 percent of patients who received the...
There are no ASCO GU Conference Coverage OBR Green articles.